Workflow
Pathway to Thrive
icon
Search documents
Chemours(CC) - 2025 Q2 - Earnings Call Presentation
2025-08-06 12:00
Second Quarter 2025 Earnings Presentation August 6, 2025 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words ...
Chemours(CC) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:00
Financial Data and Key Metrics Changes - The consolidated net sales for Q1 2025 were approximately $1.4 billion, consistent with the prior year, with a 5% increase in volume offset by a 4% price decline and a slight 1% currency headwind [20] - Adjusted EBITDA for Q1 2025 was $166 million, down from $191 million in the prior year, primarily due to lower pricing across all businesses and unfavorable currency movements [20][21] - The company reported a net loss of $4 million or $0.03 per diluted share compared to net income of $54 million or $0.36 per diluted share in the prior year [20][21] Business Segment Performance - TSS achieved net sales of $466 million, a 3% increase from the prior year, driven by a 10% volume increase, partially offset by a 6% price decline [21][22] - TT's net sales increased 1% year over year to $597 million, primarily due to a 6% increase in volume, offset by a 4% decrease in price [26] - APM reported net sales of $294 million, a 3% decrease compared to the prior year, driven by a 2% currency headwind and a 1% decrease in volume [28] Market Data and Key Metrics Changes - In TSS, Opteon refrigerants saw a 40% year-over-year net sales increase due to increased demand related to the U.S. AIM Act [6][22] - The TiO2 market in North America, Europe, and Brazil, categorized as western markets, drove a 12% sales increase sequentially, reflecting the highest first-quarter combined regional sales since 2022 [12][13] - Weaker sales were noted in China, India, and other parts of Asia and Latin America due to high levels of Chinese TiO2 product being dumped [12][13] Company Strategy and Industry Competition - The company announced a strategic agreement with Naveen Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling center needs created by AI and next-generation chips [5][6] - Chemours is focused on executing its "Pathway to Thrive" strategy, which includes driving growth in low GWP offerings and managing costs effectively [5][46] - The company anticipates a shift in its product mix towards Opteon refrigerants, projecting a 50% decrease in Freon sales in 2025 compared to the prior year [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating the impact of recent tariff announcements and emphasized the company's strong competitive position across key markets [17][18] - The company expects Q2 2025 net sales to increase in the low to mid-teens sequentially, with adjusted EBITDA anticipated to increase between 40% to 45% sequentially [39] - For the full year 2025, adjusted EBITDA is expected to be in the range of $825 million to $950 million, reflecting a refined outlook based on market dynamics [40][41] Other Important Information - The company announced a 65% reduction in its dividend to $0.08 per share, aligning with its capital allocation strategy to maintain balance sheet flexibility [34][67] - As of March 31, 2025, consolidated gross debt stood at $4.1 billion, with approximately $1.1 billion in total liquidity [31] - The company is focused on resolving legacy liabilities and has engaged with policymakers to advocate for its essential chemistry amid evolving regulatory landscapes [51][52] Q&A Session Summary Question: Can you help us think about the capacity provided by Naveen Fluorine and the timeline for commercialization? - The company is investing about $14 million in the asset, with field trials expected to require two to five tons, and anticipates customer commitments after these trials [57][59] Question: Are you expecting 2025 EBITDA to be up versus 2024? - Yes, 2025 is expected to be better than 2024 in terms of earnings, particularly in the TT segment [61][64] Question: Why now for the dividend cut, and why not eliminate it completely? - The resizing of the dividend allows for balance sheet flexibility to execute on growth investments and settle liabilities responsibly [67] Question: How have TiO2 prices been trending in regulated markets? - There is stabilization in price and volume increases in fair trade markets, with expectations for continued strength [72][73] Question: What is the outlook for supply tightness in refrigerants and cylinders? - The company is addressing cylinder shortages through additional shifts and third-party operations, expecting normalization in the next couple of months [83][84]